AAV基因转移治疗血友病A后因子VIII多年表达情况
这项1-2期试验向18例血友病A男性输注研究性AAV载体SPK-8011,设4个剂量队列,最低剂量为每公斤体重5×10^11个载体基因组,最高剂量为每公斤体重2×10^12个载体基因组。16例参与者维持因子VIII表达,年化出血率降低91.5%(95%CI 88.8至94.1)。未报告重大安全性问题。
要点
- 16/18例参与者维持因子VIII表达,可停用预防治疗并减少出血事件。
- 年化出血率中位数从输注前8.5次/年(范围0至43.0)降至输注后0.3次/年(范围0至6.5),降低91.5%(95%CI 88.8至94.1)。
- 2例因抗AAV衣壳细胞免疫反应对免疫抑制不敏感而丢失全部因子VIII表达。
核心结论
- 16/18例接受SPK-8011的参与者维持因子VIII表达,可停用预防治疗并减少出血事件,未报告重大安全性问题。
研究设计与样本
- 1-2期试验,向18例血友病A男性输注研究性AAV载体SPK-8011以在肝细胞表达因子VIII。
- 设4个剂量队列,最低剂量队列为每公斤体重5×10^11个载体基因组,最高剂量队列为每公斤体重2×10^12个载体基因组。
- 部分参与者在载体给药后52周内接受糖皮质激素,以预防或治疗推测的AAV衣壳免疫反应。
主要发现
- 中位安全性观察期为36.6个月(范围5.5至50.3)。
- 8例参与者共发生33起治疗相关不良事件,其中17起与载体相关(包括1起严重不良事件),16起与糖皮质激素相关。
- 2例参与者因抗AAV衣壳细胞免疫反应对免疫抑制不敏感而丢失全部因子VIII表达。
- 其余16例维持因子VIII表达,其中12例随访超过2年,一步法因子VIII检测显示因子VIII活性随时间未见明显下降:未接受糖皮质激素时26至52周的平均(±SD)因子VIII活性为正常值的12.9±6.9%,载体给药后>52周为正常值的12.0±7.1%,配对差值95%CI为-2.4至0.6。
- 年化出血率降低91.5%(95%CI 88.8至94.1),中位率从载体给药前的8.5次/年(范围0至43.0)降至给药后的0.3次/年(范围0至6.5)。
临床怎么用
- 原文未据此给出推荐,结论为16/18例接受SPK-8011的参与者维持因子VIII表达,可停用预防治疗并减少出血事件,未报告重大安全性问题。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The goal of gene therapy for patients with hemophilia A is to safely impart long-term stable factor VIII expression that predictably ameliorates bleeding with the use of the lowest possible vector dose. METHODS: In this phase 1-2 trial, we infused an investigational adeno-associated viral (AAV) vector (SPK-8011) for hepatocyte expression of factor VIII in 18 men with hemophilia A. Four dose cohorts were enrolled; the lowest-dose cohort received a dose of 5 × 1011 vector genomes (vg) per kilogram of body weight, and the highest-dose cohort received 2 × 1012 vg per kilogram. Some participants received glucocorticoids within 52 weeks after vector administration either to prevent or to treat a presumed AAV capsid immune response. Trial objectives included evaluation of the safety and preliminary efficacy of SPK-8011 and of the expression and durability of factor VIII. RESULTS: The median safety observation period was 36.6 months (range, 5.5 to 50.3). A total of 33 treatment-related adverse events occurred in 8 participants; 17 events were vector-related, including 1 serious adverse event, and 16 were glucocorticoid-related. Two participants lost all factor VIII expression because of an anti-AAV capsid cellular immune response that was not sensitive to immune suppression. In the remaining 16 participants, factor VIII expression was maintained; 12 of these participants were followed for more than 2 years, and a one-stage factor VIII assay showed no apparent decrease in factor VIII activity over time (mean [±SD] factor VIII activity, 12.9±6.9% of the normal value at 26 to 52 weeks when the participants were not receiving glucocorticoids vs. 12.0±7.1% of the normal value at >52 weeks after vector administration; 95% confidence interval [CI], -2.4 to 0.6 for the difference between matched pairs). The participants had a 91.5% reduction (95% CI, 88.8 to 94.1) in the annualized bleeding rate (median rate, 8.5 events per year [range, 0 to 43.0] before vector administration vs. 0.3 events per year [range, 0 to 6.5] after vector administration). CONCLUSIONS: Sustained factor VIII expression in 16 of 18 participants who received SPK-8011 permitted discontinuation of prophylaxis and a reduction in bleeding episodes. No major safety concerns were reported. (Funded by Spark Therapeutics and the National Heart, Lung, and Blood Institute; ClinicalTrials.gov numbers, NCT03003533 and NCT03432520.).
引用
- George LA, Monahan PE, Eyster ME, et al. Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A. N Engl J Med. 2021. PMID: 34788507. doi:10.1056/NEJMoa2104205
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。